Emmessar Biotech & Nutrition Ltd Stock Price Today (NSE: EMMESSA)
Fundamental Score
Emmessar Biotech & Nutrition Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Emmessar Biotech & Nutrition Ltd share price today is ₹25.84, down 2.12% on NSE/BSE as of 19 June 2026. Emmessar Biotech & Nutrition Ltd (EMMESSA) is a Small-cap company in the Commodity Chemicals sector with a market capitalisation of ₹15.95 (Cr). The 52-week high for EMMESSA share price is ₹42.90 and the 52-week low is ₹18.42. At a P/E ratio of 69.37x, EMMESSA is currently trading above its industry average P/E of 20.98x. The company has a Return on Equity (ROE) of 4.23% and a debt-to-equity ratio of 0.00.
Emmessar Biotech & Nutrition Ltd Share Price Chart — NSE/BSE Historical Performance
Emmessar Biotech & Nutrition Ltd share price chart: 1.33% return over the past month. 52-week high ₹42.90, 52-week low ₹18.42.
Emmessar Biotech & Nutrition Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹26.33 | ₹26.33 | ₹24.11 | ₹25.84 | 286.00 (Cr) | |
| ₹24.50 | ₹26.86 | ₹24.00 | ₹26.40 | 320.00 (Cr) | |
| ₹25.93 | ₹25.93 | ₹24.50 | ₹24.77 | 180.00 (Cr) | |
| ₹25.55 | ₹25.98 | ₹24.76 | ₹25.93 | 150.00 (Cr) | |
| ₹26.20 | ₹26.20 | ₹25.98 | ₹25.99 | 1.36K (Cr) | |
| ₹26.40 | ₹26.40 | ₹24.90 | ₹26.20 | 58.00 (Cr) | |
| ₹24.50 | ₹27.14 | ₹24.50 | ₹24.74 | 744.00 (Cr) | |
| ₹25.00 | ₹26.90 | ₹25.00 | ₹25.25 | 2.48K (Cr) | |
| ₹25.01 | ₹26.40 | ₹25.01 | ₹25.41 | 1.60K (Cr) | |
| ₹25.24 | ₹26.40 | ₹25.24 | ₹26.40 | 193.00 (Cr) |
Emmessar Biotech & Nutrition Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹24.50 | ₹26.86 | ₹24.00 | ₹25.84 | +5.47% | |
| ₹25.95 | ₹27.99 | ₹24.50 | ₹24.77 | -4.55% | |
| ₹23.50 | ₹27.99 | ₹23.50 | ₹26.47 | +12.64% | |
| ₹24.30 | ₹28.74 | ₹18.42 | ₹23.56 | -3.05% | |
| ₹26.70 | ₹32.60 | ₹24.29 | ₹25.91 | -2.96% | |
| ₹28.67 | ₹30.94 | ₹25.00 | ₹25.40 | -11.41% | |
| ₹31.01 | ₹32.41 | ₹27.00 | ₹29.35 | -5.35% | |
| ₹30.00 | ₹33.38 | ₹28.32 | ₹32.11 | +7.03% | |
| ₹30.62 | ₹34.49 | ₹28.11 | ₹31.03 | +1.34% | |
| ₹26.35 | ₹42.75 | ₹26.10 | ₹32.41 | +23.00% | |
| ₹29.80 | ₹29.80 | ₹25.80 | ₹26.49 | -11.11% | |
| ₹32.69 | ₹42.90 | ₹28.70 | ₹29.63 | -9.36% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Micro-cap commodity chemical play with negative profitability and high execution risk.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Emmessar Biotech's share price is around There's been no major news or announcements beyond routine compliance filings. The company confirmed the non-applicability of SEBI circular regarding funding by large corporates. December 2025 quarterly net profit showed a 576.7% YoY growth.
CORE STORY (THE REAL GAME)
This is a micro-cap commodity chemical/healthcare play trading on hopes of future growth in the Indian market. The company shifted from specialty chemicals to healthcare formulations, anticipating growth.
- Commodity chemical sector tailwinds in India
- Shift to healthcare formulations
- Micro-cap speculation
- Order wins in healthcare segment
- Significant improvement in profitability
- Acquisition by a larger player
- Micro/SME cap equals liquidity risk
- Negative sales and profit CAGR over 5 years
- High P/E ratio compared to industry
Promoter holding stable at 59.53%, FII negligible, DII at 0.19%. No significant change.
Indian chemical industry projected to grow, but faces challenges like high energy costs and regulatory hurdles.
No - Free Cash Flow 5Y: ₹3.64 Cr, but OPM deeply negative
Hoping for a turnaround in the next 3-6 months based on the shift to healthcare. Expect volatility and high risk.
Primary Thesis Risk
Inability to improve profitability and execute the healthcare strategy.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Emmessar Biotech & Nutrition Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Emmessar Biotech & Nutrition Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of EMMESSA across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (59.53%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
10 factors identified
Below-Average Return on Equity (4.23%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Margin Pressure Concerns (-29.14%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Premium Valuation Risk (P/E: 69.37x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-60.71%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-73.53%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-29.08% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-19.73% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-19.73% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Limited Institutional Interest (FII+DII: 0.19%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Emmessar Biotech & Nutrition Ltd vs Commodity Chemicals Peers
Peer Comparison - Commodity Chemicals
Compare Emmessar Biotech & Nutrition Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Emmessar Biotech & Nutrition LtdEmmessar Biotec...Selected✓ EMMESSA • 524768 | 15.1/100 | ₹25.84₹26 | ₹15.95₹15.95 | 69.37Average 69.4 Average | 4.23%Poor 4.23% Poor | 12.61%Average 12.61% Average | 0.00Excellent 0.0 Excellent | -19.73%Poor -19.73% Poor | -29.08%Poor -29.08% Poor | 0.00% |
SRF LtdSRF Ltd... SRF • 503806 | 49.8/100 | ₹2726.60₹2727 | ₹86606.52₹86606.52 | 53.54Average 53.5 Average | 10.37%Average 10.37% Average | 12.27%Average 12.27% Average | 0.35Excellent 0.3 Excellent | 4.40%Average 4.40% Average | 15.30%Excellent 15.30% Excellent | 0.25% |
Tata Chemicals LtdTata Chemicals ... TATACHEM • 500770 | 14.9/100 | ₹720.50₹721 | ₹20261.08₹20261.08 | 62.18Average 62.2 Average | 1.20%Poor 1.20% Poor | 3.96%Poor 3.96% Poor | 0.34Excellent 0.3 Excellent | -47.92%Poor -47.92% Poor | 7.53%Good 7.53% Good | 1.38% |
Deepak Fertilisers and Petrochemicals Corporation LtdDeepak Fertilis... DEEPAKFERT • 500645 | 57/100 | ₹1420.60₹1421 | ₹17120.52₹17120.52 | 17.39Average 17.4 Average | 15.56%Good 15.56% Good | 15.67%Good 15.67% Good | 0.68Good 0.7 Good | 94.55%Excellent 94.55% Excellent | 17.00%Excellent 17.00% Excellent | 0.74% |
52.8/100 | ₹502.90₹503 | ₹7381.56₹7381.56 | 11.61Average 11.6 Average | 7.08%Poor 7.08% Poor | 9.57%Poor 9.57% Poor | 0.00Excellent 0.0 Excellent | 3.30%Average 3.30% Average | 8.86%Good 8.86% Good | 3.58% | |
Ghcl LtdGhcl Ltd... GHCL • 500171 | 40.4/100 | ₹442.65₹443 | ₹5520.31₹5520.31 | 9.69Average 9.7 Average | 18.57%Good 18.57% Good | 24.19%Excellent 24.19% Excellent | 0.03Excellent 0.0 Excellent | 8.63%Good 8.63% Good | -0.75%Poor -0.75% Poor | 2.09% |
Blue Pearl Agriventures LtdBlue Pearl Agri... BPAGRI • 514440 | 19.7/100 | ₹13.75₹14 | ₹5397.73₹5397.73 | 9306.43Average 9306.4 Average | 2.12%Poor 2.12% Poor | 2.57%Poor 2.57% Poor | 0.00Excellent 0.0 Excellent | — — | 173.71%Excellent 173.71% Excellent | 0.00% |
Chemplast Sanmar LtdChemplast Sanma... CHEMPLASTS • 543336 | 24.4/100 | ₹206.06₹206 | ₹4503.74₹4503.74 | — — | -5.93%Poor -5.93% Poor | 1.83%Poor 1.83% Poor | 0.97Good 1.0 Good | — — | 28.15%Excellent 28.15% Excellent | 0.00% |
Tanfac Industries LtdTanfac Industri... TANFACIND • 506854 | 68.7/100 | ₹1984.75₹1985 | ₹4106.65₹4106.65 | 43.66Average 43.7 Average | 32.05%Excellent 32.05% Excellent | 41.76%Excellent 41.76% Excellent | 0.09Excellent 0.1 Excellent | 38.64%Excellent 38.64% Excellent | 27.58%Excellent 27.58% Excellent | 0.22% |
Gujarat Alkalies and Chemicals LtdGujarat Alkalie... GUJALKALI • 530001 | 28/100 | ₹665.45₹665 | ₹3866.17₹3866.17 | 25774.49Average 25774.5 Average | -1.13%Poor -1.13% Poor | -0.34%Poor -0.34% Poor | 0.11Excellent 0.1 Excellent | — — | 8.37%Good 8.37% Good | 3.01% |
Grauer & Weil India LtdGrauer & Weil I... GRAUWEIL • 505710 | 59.7/100 | ₹71.21₹71 | ₹3614.14₹3614.14 | 23.93Average 23.9 Average | 17.58%Good 17.58% Good | 23.34%Excellent 23.34% Excellent | 0.01Excellent 0.0 Excellent | 17.17%Excellent 17.17% Excellent | 12.90%Good 12.90% Good | 0.63% |
Top Commodity Chemicals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- SRF Ltd share price86606.52 Cr
- Tata Chemicals Ltd share price20261.08 Cr
- Deepak Fertilisers and Petrochemicals Corporation Ltd share price17120.52 Cr
- Gujarat Narmada Valley Fertilizers & Chemicals Ltd share price7381.56 Cr
- Ghcl Ltd share price5520.31 Cr
Emmessar Biotech & Nutrition Ltd PE Ratio History
Historical price-to-earnings ratio for EMMESSA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹0.61 | ₹29.35 | 48.1x |
| FY 2024 | ₹1.48 | ₹45.04 | 30.4x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Emmessar Biotech & Nutrition Ltd Quarterly Performance
Latest quarterly metrics for EMMESSA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-73.53%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-60.71%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-29.08%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-19.73%
Compounded annual net profit growth over 5 years
Emmessar Biotech & Nutrition Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for EMMESSA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Emmessar Biotech & Nutrition Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Emmessar Biotech & Nutrition Ltd (EMMESSA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Emmessar Biotech & Nutrition Ltd
About EMMESSA (Emmessar Biotech & Nutrition Ltd)
Emmessar Biotech & Nutrition Ltd is a dynamic player in the commodity chemicals sector, demonstrating a commitment to innovation and sustainable solutions. They source, manufacture..., and distribute a diverse range of essential chemical compounds that serve as vital building blocks for numerous industries. These chemicals are integral to producing everything from plastics and polymers that shape our everyday lives to advanced materials employed in construction and automotive manufacturing. EMMESSA prioritizes quality and consistency, ensuring that its products meet rigorous industry standards and customer expectations. This dedication translates into long-term partnerships with clients who rely on a dependable supply chain for their own manufacturing processes. By focusing on cost-effectiveness and operational efficiency, EMMESSA positions itself as a competitive and valuable partner in the commodity chemicals market. The company's strength lies in its robust infrastructure and a team of experienced professionals who possess deep knowledge of chemical processes and market dynamics. EMMESSA continuously invests in research and development, exploring innovative approaches to enhance product performance and minimize environmental impact. They are actively engaged in developing more sustainable alternatives and optimizing existing processes to reduce waste and energy consumption. The company’s commitment to responsible sourcing and ethical business practices ensures that its operations adhere to the highest standards of corporate social responsibility. This includes implementing strict safety protocols within its manufacturing facilities and actively participating in environmental conservation initiatives. EMMESSA's strategic approach to distribution and logistics allows them to efficiently serve a global customer base. Their network of strategically located warehouses and partnerships with reputable transportation providers ensures timely and reliable delivery of products to clients worldwide. Beyond simply supplying commodity chemicals, EMMESSA aims to be a trusted partner, offering technical expertise and support to help customers optimize their own production processes. This consultative approach strengthens customer relationships and fosters collaboration, contributing to the overall success of both EMMESSA and its clients. By focusing on customer satisfaction and continuous improvement, EMMESSA Biotech & Nutrition Ltd is poised for continued growth and success in the evolving commodity chemicals landscape.
Company Details
Key Leadership
EMMESSA Share Price: Frequently Asked Questions
What is the current share price of Emmessar Biotech & Nutrition Ltd?
Emmessar Biotech & Nutrition Ltd (EMMESSA) trades at ₹25.84 on NSE and BSE. Market cap ₹15.95 (Cr). Educational data only.
What is the P/E ratio of Emmessar Biotech & Nutrition Ltd?
Emmessar Biotech & Nutrition Ltd has a P/E of 69.37x vs industry average 20.98x.
What is the Bull Run score for Emmessar Biotech & Nutrition Ltd?
Emmessar Biotech & Nutrition Ltd has a Bull Run score of 15.1/100 based on 25+ financial parameters.
Does Emmessar Biotech & Nutrition Ltd pay dividends?
Emmessar Biotech & Nutrition Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Emmessar Biotech & Nutrition Ltd?
Emmessar Biotech & Nutrition Ltd has ROE of 4.23%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Emmessar Biotech & Nutrition Ltd?
Emmessar Biotech & Nutrition Ltd has debt-to-equity of 0.00.
Is Emmessar Biotech & Nutrition Ltd a good investment?
Bull Run gives Emmessar Biotech & Nutrition Ltd a score of 15.1/100. This is not investment advice — consult a SEBI-registered advisor.